Pro-Dex (PDEX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Pro-Dex

NasdaqCM•Healthcare•Medical Instruments & Supplies

$62.38+1.82(0.03%)After hours

Market Cap

$194.78M

P/E

16.2x

P/S

2.4x

P/B

3.9x

Pro-Dex, Inc. designs, develops, manufactures, and repairs powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; manufactures and sells rotary air motors to various industries; and precision machined parts and assemblies for the aerospace and defense industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

How this company scores

GoodMetricSide Score: 69/100

Strongest: Growth (21/25); weakest: Cash & Earnings Quality (14/25).

Profitability19/25

Growth21/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality14/25

Strengths

Strong marginsHigh ROEInterest easily coveredConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 16.2x5y range 0.0x – 32.3x

Currently above its 20-quarter median.

P/S · 2.4x5y range 0.0x – 2.5x

Currently above its 20-quarter median.

P/B · 3.9x5y range 0.0x – 4.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.3x) — earnings may be inflated by non-cash items or aggressive accounting.

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $194.78M

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $79.58M
Q. Revenue: $20.56M
TTM EBITDA: $14.88M
TTM Op. Income: $13.40M
Q. Op. Income: $3.52M
TTM Net Income: $12.03M
Q. Net Income: $3.05M
EPS: $0.95
Shares Out.: $3.21M

$79.58M in TTM revenue grew 13.3% YoY, reaching $20.56M last quarter. TTM EBITDA of $14.88M and TTM operating income of $13.40M show growth is flowing through to the bottom line. TTM net income of $12.03M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 33.4%
EBITDA Margin: 19.1%
Op. Margin: 17.1%
Net Margin: 14.8%

Op. margin of 17.1% is up 0.3% YoY — cost efficiency is improving. Net margin at 14.8% and gross margin of 33.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 2% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 16.2x
P/S Ratio: 2.4x
P/B Ratio: 3.9x

At 16.2x P/E, the stock trades within typical market levels. P/S of 2.4x and P/B of 3.9x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 4 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $76.59M
Cash: $11.76M
Long-Term Debt: N/A
Book Value: $49.35M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $6.49M
TTM Free Cash Flow: $10.69M
FCF Margin: 13.4%
FCF / Net Income: 0.9

TTM FCF of $10.69M on $6.49M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 614% — an improving trend.